Generate Biomedicines (NASDAQ:GENB) Stock Rating Reaffirmed as Buy by HC Wainwright

Key Points

• HC Wainwright reaffirmed a Buy rating on Generate Biomedicines with a $30 price target, implying 119.14% upside from the previous close.
• Analyst sentiment is broadly positive: six analysts rate the stock Buy, one rates it Hold and one rates it Sell, producing a consensus “Moderate Buy” rating and an average price target of $26.40.
• GENB opened at $13.69, with a $1.76 billion market capitalization, while its latest quarterly loss of $0.52 per share missed estimates and revenue totaled $6.31 million.

Generate Biomedicines (NASDAQ:GENB - Get Free Report)'s stock had its "buy" rating reiterated by analysts at HC Wainwright in a report issued on Monday, Benzinga reports. They presently have a $30.00 price target on the stock. HC Wainwright's price target would suggest a potential upside of 119.14% from the stock's previous close.

Several other research firms have also recently commented on GENB. Weiss Ratings upgraded Generate Biomedicines from a "sell (d)" rating to a "sell (d+)" rating in a research note on Friday, September 25th. Wall Street Zen upgraded Generate Biomedicines from a "sell" rating to a "hold" rating in a research note on Saturday, September 26th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Generate Biomedicines presently has an average rating of "Moderate Buy" and an average price target of $26.40.

Generate Biomedicines Stock Performance

GENB stock opened at $13.69 on Monday. The company has a market capitalization of $1.76 billion and a P/E ratio of -8.61. Generate Biomedicines has a twelve month low of $11.00 and a twelve month high of $22.67. The business has a 50 day simple moving average of $15.53 and a 200-day simple moving average of $14.36.

Generate Biomedicines (NASDAQ:GENB - Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The firm had revenue of $6.31 million during the quarter. Research analysts predict that Generate Biomedicines will post -2.29 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Braidwell LP purchased a new position in Generate Biomedicines in the second quarter worth $55,398,000. State Street Corp purchased a new position in Generate Biomedicines in the second quarter worth $8,883,000. The Manufacturers Life Insurance Company purchased a new position in Generate Biomedicines in the second quarter worth $1,431,000. Bank of New York Mellon Corp purchased a new position in Generate Biomedicines in the second quarter worth $967,000. Finally, Squarepoint Ops LLC purchased a new position in Generate Biomedicines in the second quarter worth $530,000.

Generate Biomedicines Company Profile

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.